Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment

评估多层次沟通活动以增加艾滋病毒疫苗试验注册人数

• 批准号: 10625227
• 负责人: Michele Peake Andrasik
• 金额: $ 65.12万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-19 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625227
• 关键词: Address; Advertising; Affect; Awareness; Behavioral; Black, Indigenous, People of Color; COVID-19; COVID-19 Prevention Network; COVID-19 pandemic; COVID-19 vaccine; Classification; Collaborations; Communication; Communities; Data; Development; Dissemination and Implementation; Educational Curriculum; Effectiveness; Electronic Mail; Enrollment; Facebook; Focus Groups; Funding; Future; Goals; Government; HIV; HIV Vaccine Trials Network; HIV vaccine; Health; Health Services; Instagram; International; Interruption; Knowledge; Lesbian Gay Bisexual Transgender Queer; Longterm Follow-up; Marketing; Measures; Media Campaign; Medical Research; Misinformation; Modeling; Outcome; Participant; Patient Recruitments; Performance; Phase; Phase III Clinical Trials; Population Heterogeneity; Positioning Attribute; Preventive; Protocols documentation; Published Comment; Registries; Research; Research Personnel; Series; Surveys; Taxonomy; Testing; Time; Training; Trust; Twitter; United States; Vaccine Clinical Trial; Vaccines; Visit; Work; clinical research site; clinical training; combat; community based participatory research; community engagement; community partnership; design; early phase trial; efficacy testing; eligible participant; equity, diversity, and inclusion; evidence base; experience; forging; health communication; implementation research; improved; innovation; marginalized community; multidisciplinary; outreach; participant enrollment; primary outcome; programs; recruit; seropositive; social media; social stigma; trend analysis; trial enrollment; trustworthiness; vaccine hesitancy; vaccine trial; virtual; web site

Project Summary/Abstract The HIV Vaccine Trials Network (HVTN) has experienced significant challenges recruiting participants in early-stage HIV vaccine clinical trials. Formidable barriers to participation in HVTN preventive HIV early phase trials, including lack of HIV public urgency, numerous study visits, long-term follow-up, vaccine induced seropositivity and HIV stigma, have resulted in significant challenges enrolling participants into these trials. We will co-refine an existing media campaign, develop, test and evaluate a multilevel communication strategy to address some of these crucial concerns and strengthen our reputation of trustworthiness in marginalized communities disproportionately affected by HIV to increase their enrollment into early-stage HIV vaccine trials. Over the next 7 years, the HVTN will focus on the early phase trial program to move the field forward and to identify products efficiently and effectively for later efficacy testing. This will require the development and deployment of evidence-based strategies to combat misinformation and to strengthen community engagement. Our team and the clinical research sites in our Network have forged longstanding community partnerships with diverse stakeholders. During our phase 3 clinical trials for the US government-funded COVID-19 vaccine clinical trials we developed new strategies to supplement our community engagement program: (1) a consumer-driven marketing and advertising campaign; (2) virtual town halls and listening sessions; and (3) the use of expert panels to review protocols and provide guidance and direction. We will build on this work to inform our HIV strategy. We assembled an experienced team of diverse researchers to accomplish the following aims: 1) Identify components of an initial media campaign that impact HIV vaccine trial registration and develop a multilevel communication strategy; 2) Evaluate the impact of the multilevel communication strategy on Phase I HIV vaccine trial registration; and 3) Determine if the multilevel communication strategy generates public engagement with vaccines and vaccine trials. This project will be the first large-scale communication study conducted in the United States to improve community awareness of and engagement with HIV vaccine trial research. It will assess misinformation and engagement with this strategy to inform current and future HIV vaccine trials recruitment and is expected to have a positive health impact by establishing robust strategies to improve diversity, equity, and inclusion in Phase 1 preventive HIV vaccine trials.

项目概要/摘要 HIV 疫苗试验网络 (HVTN) 在招募方面遇到了重大挑战 早期艾滋病毒疫苗临床试验的参与者。参与的巨大障碍 在 HVTN 预防性 HIV 早期试验中，包括缺乏 HIV 公众紧迫感，许多 研究访问、长期随访、疫苗诱导的血清阳性和艾滋病毒耻辱，已经 导致招募参与者参加这些试验面临重大挑战。我们将共同完善 现有的媒体活动，开发、测试和评估多层次的沟通 解决其中一些关键问题并加强我们的声誉的战略 受艾滋病毒影响不成比例的边缘化社区的可信度 增加他们参与早期艾滋病毒疫苗试验的人数。未来7年， HVTN 将重点关注早期试验计划，以推动该领域向前发展并确定 产品高效且有效地用于后期功效测试。这将需要 制定和部署基于证据的战略，以打击错误信息和 加强社区参与。我们的团队和我们的临床研究中心 Network 与不同的利益相关者建立了长期的社区合作伙伴关系。 在我们对美国政府资助的 COVID-19 疫苗临床进行 3 期临床试验期间 我们制定了新的试验策略来补充我们的社区参与计划： (1) 消费者驱动的营销和广告活动； (2) 虚拟市政厅和 聆听会议； (3) 利用专家小组审查方案并提供 指导和方向。我们将在这项工作的基础上为我们的艾滋病毒战略提供信息。我们 组建了一支由不同研究人员组成的经验丰富的团队，以实现以下目标： 1) 确定影响 HIV 疫苗试验的初始媒体活动的组成部分 注册并制定多层次沟通策略； 2) 评估影响 第一阶段艾滋病疫苗试验注册的多层次沟通策略；和 3) 确定多层次沟通策略是否能引起公众参与 疫苗和疫苗试验。该项目将是第一个大规模的传播研究 在美国进行，旨在提高社区意识和参与度 与艾滋病毒疫苗试验研究。它将评估错误信息和对此的参与 为当前和未来的艾滋病毒疫苗试验招募提供信息的战略，预计将 通过制定强有力的战略来改善多样性，对健康产生积极的影响， 公平性，以及参与第一阶段预防性艾滋病毒疫苗试验。